Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.